A case of Beh‡et's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

被引:95
作者
Hirano, Toru [1 ]
Ohguro, Nobuyuki [2 ]
Hohki, Satoshi [3 ]
Hagihara, Keisuke [1 ]
Shima, Yoshihito [1 ]
Narazaki, Masashi [1 ]
Ogata, Atsushi [1 ]
Yoshizaki, Kazuyuki [4 ]
Kumanogoh, Atsushi [1 ]
Kishimoto, Tadamitsu [5 ]
Tanaka, Toshio [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Resp Med Allergy & Rheumat Dis, Suita, Osaka 5650871, Japan
[2] Osaka Koseinenkin Hosp, Dept Ophthalmol, Osaka, Japan
[3] Toyama Univ, Dept Ophthalmol, Grad Sch Med & Pharmaceut Sci, Toyama 930, Japan
[4] Osaka Univ, Ctr Adv Sci & Innovat, Suita, Osaka 5650871, Japan
[5] Osaka Univ, Lab Immune Regulat, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan
关键词
Behcet's disease; IL-6; Tocilizumab; GENOME-WIDE ASSOCIATION; BEHCETS-DISEASE; CEREBROSPINAL-FLUID; INTERLEUKIN-6; IL23R-IL12RB2; GENERATION; THERAPY; CELLS; IL10;
D O I
10.1007/s10165-011-0497-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 47-year-old female patient with Beh double dagger et's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Beh double dagger et's disease.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 24 条
[1]  
[Anonymous], 1987, CLASS CRIT BEHC DIS
[2]   Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells [J].
Bettelli, E ;
Carrier, YJ ;
Gao, WD ;
Korn, T ;
Strom, TB ;
Oukka, M ;
Weiner, HL ;
Kuchroo, VK .
NATURE, 2006, 441 (7090) :235-238
[3]   Behcet's disease: evaluation of a new instrument to measure clinical activity [J].
Bhakta, BB ;
Brennan, P ;
James, TE ;
Chamberlain, MA ;
Noble, BA ;
Silman, AJ .
RHEUMATOLOGY, 1999, 38 (08) :728-733
[4]   Treatment strategies for Behcet's disease [J].
Fresko, Izzet ;
Yazici, Hasan .
EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (18) :3211-3219
[5]   Translation, adaptation, and validation of the SF-36 Health Survey for use in Japan [J].
Fukuhara, S ;
Bito, S ;
Green, J ;
Hsiao, A ;
Kurokawa, K .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1998, 51 (11) :1037-1044
[6]   Cytokine profile in Behcet's disease patients - Relationship with disease activity [J].
Hamzaoui, K ;
Hamzaoui, A ;
Guemira, F ;
Bessioud, M ;
Hamza, M ;
Ayed, K .
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2002, 31 (04) :205-210
[7]   Blockade of Interleukin-6 Signaling Suppresses Not Only Th17 but Also Interphotoreceptor Retinoid Binding Protein-Specific Th1 by Promoting Regulatory T Cells in Experimental Autoimmune Uveoretinitis [J].
Haruta, Hiroshi ;
Ohguro, Nobuyuki ;
Fujimoto, Minoru ;
Hohki, Satoshi ;
Terabe, Fumitaka ;
Serada, Satoshi ;
Nomura, Shintaro ;
Nishida, Kohji ;
Kishimoto, Tadamitsu ;
Naka, Tetsuji .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2011, 52 (06) :3264-3271
[8]   EULAR recommendations for the management of Behcet disease [J].
Hatemi, G. ;
Silman, A. ;
Bang, D. ;
Bodaghi, B. ;
Chamberlain, A. M. ;
Gul, A. ;
Houman, M. H. ;
Kotter, I. ;
Olivieri, I. ;
Salvarani, C. ;
Sfikakis, P. P. ;
Siva, A. ;
Stanford, M. R. ;
Stuebiger, N. ;
Yurdakul, S. ;
Yazici, H. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (12) :1656-1662
[9]   Cerebrospinal fluid interleukin-6 in progressive neuro-Behcet's syndrome [J].
Hirohata, S ;
Isshi, K ;
Oguchi, H ;
Ohse, T ;
Haraoka, H ;
Takeuchi, A ;
Hashimoto, T .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1997, 82 (01) :12-17
[10]   STREPTOCOCCAL-RELATED ANTIGENS STIMULATE PRODUCTION OF IL6 AND INTERFERON-GAMMA BY T-CELLS FROM PATIENTS WITH BEHCETS-DISEASE [J].
HIROHATA, S ;
OKA, H ;
MIZUSHIMA, Y .
CELLULAR IMMUNOLOGY, 1992, 140 (02) :410-419